Skip to main content
Top
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Neuroblastoma | Research

Bilateral adrenal neuroblastoma: peculiar pattern of a rare pediatric presentation

Authors: Mohamed Fawzy, Gehad Ahmed, Yasser Youssef, Naglaa Elkinaai, Amal Refaat, Mai Amr Elahmadawy, Fadwa Said, Salma Elmenawi

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Background

Bilateral suprarenal neuroblastoma (BSN) is a rare presentation. Few previously published literature showed BSN patients to have favorable pattern and prognosis. This study aim was to evaluate clinical and biological features in relation to outcome of Egyptian patients with BSN.

Methods

Included patients were diagnosed from 2007 to 2017, retrospectively. Tissue biopsy, imaging and bone marrow were evaluated at presentation. Clinical, demographic, biological variables and risk group were determined and analyzed in relation to overall (OS) and event-free-survival (EFS).

Results

BSN patients (n = 33) represented 2% of hospital patients with neuroblastoma during the 10-year study period, 17 were males and 16 were females. Twenty-four patients (72.7%) were infants, and 9 patients (27.3%) were above 1 year of age (range: 1 month to 3 years). Metachronous disease was present in only one patient. Amplified MYCN was found in 10 patients. Initially, most patients (n = 25) had distant metastasis, 6 had stage 3 versus 2 stage 2. Fifteen were high risk (HR), 15 intermediate (IR), 1 low risk (LR) and 2 were undetermined due to inadequate tissue biopsy. Three-year OS for HR and IR patients were 40.5% and 83.9% versus 23.2% and 56.6% EFS; respectively.

Conclusion

BSN treatment is similar to unilateral disease. A more conservative surgical approach with adrenal tissue preservation on less extensive side should be considered. Biological variables and extent of disease are amongst the most important prognostic determinants. Future studies are warranted to further address the biologic profiling of BSN and highlight prognostic significance of size difference between both adrenal sides.
Literature
5.
go back to reference Johnston DL, Sweeney B, Halton JM. Bilateral adrenal neuroblastoma stage V disease. J Pediatr Hematol Oncol. 2007;29:652–5.CrossRefPubMed Johnston DL, Sweeney B, Halton JM. Bilateral adrenal neuroblastoma stage V disease. J Pediatr Hematol Oncol. 2007;29:652–5.CrossRefPubMed
10.
go back to reference Shimada H, et al. The International neuroblastoma pathology classification (the Shimada system)-PubMed. Cancer. 1999;86(2):364–72.CrossRefPubMed Shimada H, et al. The International neuroblastoma pathology classification (the Shimada system)-PubMed. Cancer. 1999;86(2):364–72.CrossRefPubMed
12.
17.
21.
go back to reference Shaw H, Sabio A. Bilateral adrenal neuroblastoma. Am J Pediatr Hematol Oncol. 1984;6(1):3. Shaw H, Sabio A. Bilateral adrenal neuroblastoma. Am J Pediatr Hematol Oncol. 1984;6(1):3.
Metadata
Title
Bilateral adrenal neuroblastoma: peculiar pattern of a rare pediatric presentation
Authors
Mohamed Fawzy
Gehad Ahmed
Yasser Youssef
Naglaa Elkinaai
Amal Refaat
Mai Amr Elahmadawy
Fadwa Said
Salma Elmenawi
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00966-6

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine